ProQR stock rating reiterated by Cantor Fitzgerald ahead of key 2H25 data

Investing.com - Cantor Fitzgerald has reiterated an Overweight rating and $8.00 price target on ProQR Therapeutics N.V. (NASDAQ:PRQR), currently trading at $2.35, following virtual investor meetings with the Netherlands-based company’s leadership team. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $4 to $14.

The meetings included CEO Daniel de Boer, CFO Dennis Hom and CMO Cristina Lopez Lopez, both of whom joined in April, as well as IR Sarah Kiely, according to Cantor Fitzgerald.

The timing of these discussions is significant as the second half of 2025 represents a critical inflection point for ADAR editing technology and ProQR specifically, with clinical data expected from three independent programs.

ProQR plans to announce initial healthy volunteer data for its NTCP-targeting oligonucleotide for cholestatic disease in the fourth quarter of 2025, while two other companies will also report clinical updates on their ADAR editing programs.

Cantor Fitzgerald believes these upcoming data releases spanning three companies, two indications (cholestatic disease and AATD), and two delivery modalities (LNP and GalNAc) will validate ADAR editing as a new therapeutic approach in oligonucleotide treatments.

In other recent news, ProQR Therapeutics has submitted a Clinical Trial Application to the European Medicines Agency for its RNA editing therapy AX-0810, marking a significant milestone for the company. This Phase 1 clinical trial aims to evaluate the safety, tolerability, and pharmacokinetics of AX-0810 in healthy volunteers, with initial data expected in the fourth quarter of 2025. The therapy targets NTCP to treat cholestatic liver diseases by reducing toxic bile acid accumulation. Analysts have taken note, with Cantor Fitzgerald maintaining an Overweight rating and an $8.00 price target, citing ProQR’s leading position in RNA editing and promising clinical program. Similarly, JMP Securities reiterated a Market Outperform rating with the same price target, emphasizing the fundamentally derisked nature of the AX-0810 trial. Evercore ISI also initiated coverage with an Outperform rating but set a slightly lower price target of $5.00, highlighting ProQR as a "true" biotech investment despite high biology risks. The firm’s analysis suggests that ProQR’s current stock price does not reflect its potential, pointing to strategic options that offer underpriced optionality. These developments underscore ProQR’s continued progress in advancing its RNA editing platform into clinical stages.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.